pindolol has been researched along with Muscular Dystrophy in 1 studies
Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638)
pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Steinfath, M | 1 |
| Lavicky, J | 1 |
| Schmitz, W | 1 |
| Scholz, H | 1 |
| Döring, V | 1 |
| Kalmár, P | 1 |
1 other study available for pindolol and Muscular Dystrophy
| Article | Year |
|---|---|
Changes in cardiac beta-adrenoceptors in human heart diseases: relationship to the degree of heart failure and further evidence for etiology-related regulation of beta 1 and beta 2 subtypes.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aortic Valve; Cardiomyopathy, Hypertrophic; Down-Reg | 1993 |